Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Jones

Pulmonary Disease Abingdon, VA Medical Doctor

NPI 1629392410 CMS profile 28780

24530 Falcon Place Blvd Ste 101, Abingdon, VA 24211

Open in the dashboard

General payments

$11,988

422 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Jones of Abingdon, VA is reported in the CMS Open Payments database as having received $11,988 across 422 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,823 20
2024 General $624 34
2023 General $4,582 70
2022 General $1,452 77
2021 General $1,369 87
2020 General $1,222 72
2019 General $915 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Jones
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Robert Jones were reported at $1,823. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Robert Jones Pulmonary Disease median Middle half National median
2019 $915 $377 $109–$1,340 $163
2020 $1,222 $230 $56–$907 $114
2021 $1,369 $269 $68–$1,072 $132
2022 $1,452 $390 $100–$1,457 $149
2023 $4,582 $419 $114–$1,659 $160
2024 $624 $476 $123–$1,818 $164
2025 $1,823 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $4,831 8 payments
  2. GlaxoSmithKline, LLC. $2,135 146 payments
  3. AstraZeneca Pharmaceuticals LP $878 52 payments
  4. Actelion Pharmaceuticals US, Inc. $859 35 payments
  5. Insmed, Inc. $530 32 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $402 26 payments
  7. Grifols USA, LLC $280 19 payments
  8. Electromed, Inc. $226 11 payments
  9. Baxter Healthcare $217 10 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $182 8 payments
  11. Other $1,447 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,438 417 payments
  2. Education $4,550 5 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $4,831 8 payments
  2. TRELEGY ELLIPTA $993 73 payments
  3. NUCALA Immunology $722 45 payments
  4. UPTRAVI $536 22 payments
  5. Arikayce $513 31 payments
  6. OPSUMIT $399 16 payments
  7. FASENRA $323 14 payments
  8. Prolastin-C Liquid $280 19 payments
  9. SPIRIVA RESPIMAT $250 16 payments
  10. NUCALA Respiratory $232 11 payments
  11. Other $3,598 193 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,297

Median for Critical Care (Intensivists): 406

Drug cost

$1,059,315

Median for Critical Care (Intensivists): $197,260

Branded share of claims

73.6%

Median for Critical Care (Intensivists): 69%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 39 $541,696
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 313 $273,734
Dupixent Pen Dupilumab Brand 12 $52,955
Nucala Mepolizumab Brand 14 $51,644
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 37 $19,701
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 26 $19,042
Breo Ellipta Fluticasone/Vilanterol Brand 33 $17,245
Symbicort Budesonide/Formoterol Fumarate Brand 48 $16,935
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 32 $14,925
Bevespi Aerosphere Glycopyrrolate/Formoterol Fum Brand 24 $10,340

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$94,597

Medicare's payments for the services billed

Medicare patients

261

Average age 74

Services billed

1,366

140 women, 121 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 64%
Ischemic heart disease 52%
Arthritis 51%
Chronic kidney disease 35%
Diabetes 32%
Cancer 29%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $108
$108 14 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $74
$74 313 —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $55
  • GENZYME CORPORATION $18
$73 12 —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $39
  • Amgen Inc. $18
$57 — —
Arikayce
  • Insmed, Inc. $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

422 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record